MIR Stock Overview
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MedMira Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.09 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.07 |
| Beta | 11.04 |
| 1 Month Change | 0% |
| 3 Month Change | -5.26% |
| 1 Year Change | 0% |
| 3 Year Change | -48.57% |
| 5 Year Change | 800.00% |
| Change since IPO | -99.14% |
Recent News & Updates
Shareholder Returns
| MIR | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 12.5% | 0.2% | -0.2% |
| 1Y | 0% | -32.1% | 6.1% |
Return vs Industry: MIR exceeded the Canadian Medical Equipment industry which returned -32.1% over the past year.
Return vs Market: MIR underperformed the Canadian Market which returned 6.1% over the past year.
Price Volatility
| MIR volatility | |
|---|---|
| MIR Average Weekly Movement | 12.5% |
| Medical Equipment Industry Average Movement | 11.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MIR has not had significant price volatility in the past 3 months.
Volatility Over Time: MIR's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Hermes Chan | www.medmira.com |
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests.
MedMira Inc. Fundamentals Summary
| MIR fundamental statistics | |
|---|---|
| Market cap | CA$63.16m |
| Earnings (TTM) | -CA$2.92m |
| Revenue (TTM) | CA$407.78k |
154.9x
P/S Ratio-21.6x
P/E RatioIs MIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIR income statement (TTM) | |
|---|---|
| Revenue | CA$407.78k |
| Cost of Revenue | CA$911.96k |
| Gross Profit | -CA$504.18k |
| Other Expenses | CA$2.42m |
| Earnings | -CA$2.92m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0042 |
| Gross Margin | -123.64% |
| Net Profit Margin | -717.02% |
| Debt/Equity Ratio | -61.7% |
How did MIR perform over the long term?
See historical performance and comparison